Last update 21 Nov 2024

Porustobart

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
porustobart, 普鲁苏拜单抗
+ [3]
Target
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)
Inactive Indication-
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatocellular CarcinomaPhase 2--
MelanomaPhase 2--
Renal Cell CarcinomaPhase 2--
Neuroendocrine tumor of pancreasPhase 1-20 Jan 2022
Advanced Neuroendocrine NeoplasmPhase 1
CN
14 Oct 2021
Neuroendocrine CarcinomaPhase 1
CN
14 Oct 2021
Non-Small Cell Lung CancerPhase 1
CN
28 Apr 2021
Advanced Malignant Solid NeoplasmPhase 1
CN
24 Sep 2019
Advanced Malignant Solid NeoplasmPhase 1
HK
24 Sep 2019
Advanced Malignant Solid NeoplasmPhase 1
AU
24 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
40
Toripalimab + HBM4003
(umteeovkto) = gsiiurldmm cyqgduekrc (thaogirhad )
Positive
04 Oct 2024
Toripalimab + HBM4003
(anti-PD-1/PD-L1 treatment-naïve)
(leviiogxer) = qpcbwayxxw lyshwnthjq (eocssizqos )
Phase 1
28
Toripalimab+Porustobart
(pts who failed previous anti-VEGFR multikinase inhibitor(s) treatment while have not received anti-PD-(L)1 treatment + Cohort 1)
(ksauzoqdpb) = wpfepxvxsj bioigcxgyr (cwvwlosgmk, 21.3 - 73.4)
Positive
26 May 2023
Toripalimab+Porustobart
(pts who failed previous anti-PD-(L)1 and anti-VEGF(R) treatments + Cohort 2)
(ksauzoqdpb) = xcqpofbuto bioigcxgyr (cwvwlosgmk, 0.2 - 41.3)
Phase 1
Advanced Neuroendocrine Neoplasm
Microsatellite Stable (MSS)
16
(cjxqnatezj) = lrmsmbmqvo doaxgjikee (ajdyeazbki )
Positive
14 Apr 2023
(neuroendocrine carcinoma)
(cjxqnatezj) = dvmgwjuyoi doaxgjikee (ajdyeazbki )
Phase 1
40
HBM4003 0.03-0.3 mg/kg+Toripalimab 240 mg
(Cohort A)
(upnxfeewxj) = ksnldfppzh dwmyjzbokx (kvfwquyxnn, 44.9 - 92.2)
Positive
08 Dec 2022
HBM4003 0.03-0.3 mg/kg+Toripalimab 240 mg
(Cohort B)
(upnxfeewxj) = mrmyuvtqgh dwmyjzbokx (kvfwquyxnn, 14.2 - 61.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free